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OBJECTIVES: To assess the budgetary impact of XELOX (com-
bination regimen of Xeloda plus oxaliplatine) as a treatment
option in colorectal cancer in Italy. METHODS: A matrix model
was developed to estimate the budgetary impact of XELOX from
the perspective of the health care purchaser in Italy in 2008. The
analysis was performed for patients with colorectal cancer receiv-
ing 5-FU, FOLFOX-4 (or FOLFOX-6 or FOLFOX-6 modiﬁed),
FOLFIRI, Xeloda (capecitabine), who are eligible for treatment
with XELOX. Data sources used include published literature,
ofﬁcial Italian price/tariff lists, and national population statistics.
The analysis covers adjuvant therapy for colon cancer and 1st
and 2nd line treatment in metastatic colorectal cancer (mCRC)
over a 5-year time horizon. The perspective of the analysis was
that of the NHS in Italy in 2008. RESULTS: The analysis shows
that the total treatment costs decrease when XELOX is intro-
duced as a treatment option in colorectal cancer. The introduc-
tion of XELOX leads to cost savings at the national level of €65
million over a period of 5 years, when the FOLFOX regimen
consists of FOLFOX-4. The use of XELOX leads to additional
costs of €154 million for XELOX, but these costs are offset by
cost savings for the other regimens and especially FOLFOX
(€171 million) and FOLFIRI (€26 million). For FOLFOX-6 and
FOLFOX-6 modiﬁed the cost savings are respectively €52 and of
€22 million. Sensitivity analyses conﬁrmed the robustness of the
outcome of the model. CONCLUSIONS: The use of XELOX
leads to a positive impact on the national drug budget in terms of
costs savings in patients with colorectal cancer.
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OBJECTIVES: To estimate the impact on the budget of the
Public Payer in Poland of the continuation of docetaxel reim-
bursement in the neoadjuvant therapy of locally advanced breast
cancer (LABC) and palliative therapy of metastatic breast cancer
(MBC) due to rising needs. METHODS: Analysis was performed
from the public payers’ perspective (National Health Fund) in
Poland. Two scenarios were compared: present and future. Doc-
etaxel is reimbursed in Poland for patients who fulﬁll special
requirements (limited reimbursement). In the “present scenario”
it was assumed that the number of patients is equal to the
number of patients treated in 2007 year. In the “future scenario”
it was assumed that the target population for docetaxel treatment
will increase in the following years 2008–2012 due to better
patient diagnosis and increase in disease incidence. for patients
who fulﬁll special requirements (limited reimbursement). In the
“present scenario” it was assumed that the number of patients is
equal to the number of patients treated in 2007 year. In the
“future scenario” it was assumed that the target population for
docetaxel treatment will increase in the following years 2008–
2012 due to better patient diagnosis and increase in disease
incidence. Two scenarios were compared: present and future.
Docetaxel is reimbursed in for patients who fulﬁll special require-
ments (limited reimbursement). In the “present scenario” it was
assumed that the number of patients is equal to the number of
patients treated in 2007 year. In the “future scenario” it was
assumed that the target population for docetaxel treatment will
increase in the following years 2008–2012 due to better patient
diagnosis and increase in disease incidence. RESULTS: Estimated
number of patients who will be treated (with restrictions) with
docetaxel will increase from 2278 in 2008 to 2550 in 2012.
Compared to 2007 total increase in number of patients will
amount from 135 to 407 patients annually. Assuming continua-
tion of docetaxel reimbursement in the treatment of LABC and
MBC in years 2008–2012, the incremental expenses of the Public
Payer to ﬁnance the treatment with docetaxel will amount 3,28
mln PLN in 2008 up to 11,23 mln PLN in 2012. Incremental
QALYs will amount from 66 to 233 in 2008 and 2012 respec-
tively. Incremental LYG will amount from 76 to 254 years in
2008 to 2012 respectively. CONCLUSIONS: Continuation of
docetaxel reimbursement in the treatment of LABC and MBC
will not considerably inﬂuence the expenses of the Public Payer in
Poland. Treatment with docetaxel improves survival and func-
tional outcomes compared with standard care. Discontinuation
of the therapeutic program reimbursement would cause signiﬁ-
cant decrease of the total incremental effect among patients with
locally advanced and metastatic breast cancer. . Treatment with
docetaxel improves survival and functional outcomes compared
with standard care. Discontinuation of the therapeutic program
reimbursement would cause signiﬁcant decrease of the total
incremental effect among patients with locally advanced and
metastatic breast cancer.
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OBJECTIVES: To demonstrate the pharmacoeconomic savings
provided by panitumumab (Vectibix®), a fully human anti-
EGFR monoclonal antibody (mAB) when compared with cetux-
imab (Erbitux®), a chimeric mAB, based on practical usage
considerations in metastatic colorectal cancer (mCRC) patients,
from the Italian Payers’ perspective. METHODS: The model
demonstrated the annual savings provided by panitumumab
versus cetuximab in a cohort of patients by grouping them into
three distinct areas; low-weight patient savings, administration
savings and safety savings. The products were compared based
on dosing, administration and safety data from the product
labels. Given the lower incidence of grade IV infusion reactions
expected with panitumumab compared with cetuximab, safety
savings were calculated by multiplying the comparative differ-
ence in frequency of infusion reactions by the Diagnosis-Related
Group (DRG) for an anaphylactic shock. Administration savings
compared the dosing schedules of panitumumab (biweekly) and
cetuximab (weekly). Therapy visit costs were based on national
tariffs (outpatient DRGs). For the average patient, with a weight
of 73 kg and a surface area of 1.7 m2, panitumumab and cetux-
imab are priced at parity. However, over a range of patients, the
average cost for panitumumab will be lower. The model used the
normal distribution and the mean and standard deviations for
weight and surface area, gained from an Italian retrospective
patient survey, to deﬁne the cohort and calculate average savings
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